Drug recall · January 31, 2018
DOXOrubicin Hydrochloride Liposome Injection recall
Why: Lack Of Assurance Of Sterility
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
DOXOrubicin Hydrochloride Liposome Injection, 20 mg/10 ml (2 mg/mL), 10 mL Single Use Vial, Distributed by: Sun Pharmaceutical Industries , Inc. Cranbury, NJ 08512. Manufactured by: Sun Pharmaceutical Ind. Ltd. Halol-Baroda Highway. Halol-389 350, Gujarat, India. NDC 47335-049-40
- Lots / codes
Lot # JKS0403A Exp 02/2019
- Quantity
- 393 vials
- Company
- Sun Pharmaceutical Industries, Inc., Cranbury, NJ
- Distribution
- Product was distributed nationwide in the USA
- Initiated
- January 16, 2018 · Voluntary: Firm initiated
- Classified
- January 19, 2018
- Reported
- January 31, 2018
- Ended
- September 14, 2018
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Doxorubicin
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.